Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001939477 | SCV002231862 | pathogenic | Mucopolysaccharidosis, MPS-IV-B; GM1 gangliosidosis | 2021-05-17 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Lys381Serfs*2) in the GLB1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GLB1 are known to be pathogenic (PMID: 18524657). This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with GLB1-related conditions. For these reasons, this variant has been classified as Pathogenic. |
Myriad Genetics, |
RCV002307812 | SCV002602237 | likely pathogenic | GM1 gangliosidosis type 2; GM1 gangliosidosis type 3; Infantile GM1 gangliosidosis | 2021-12-22 | criteria provided, single submitter | clinical testing | NM_000404.2(GLB1):c.1142delA(K381Sfs*2) is expected to be pathogenic in the context of GLB1-related disorders. This variant is predicted to lead to an abnormal or absent protein product due to the creation of a premature termination codon in GLB1, a gene where loss-of-function variants are known to be pathogenic. Please note: this variant was assessed in the context of healthy population screening. |